Tune Therapeutics, a new biotech company with roots in Seattle, has developed TEMPO, a epigenomic therapy platform. TEMPO can find epigenomic elements contributing to genetic diseases or cancers and fix them.
Tune Therapeutics plans to move “from proof of concept in rare, single-gene disorders to common conditions that aren’t linked to a single gene mutation – but are treatable through epigenomic control,” said Charles Gersbach, acting chief scientific officer.